GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hangzhou Biotest Biotech Co 688767.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

38.03

+3.34%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Hangzhou Biotest Biotech Co

Its shares trade on Shanghai under the ticker 688767.SS. It has been listed since 8 September 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥448.4m and net income of CN¥46.8m. At that date it held total assets of CN¥2.54bn and shareholders' equity of CN¥2.37bn.

Hangzhou Biotest Biotech Co., Ltd. engages in the research, development, production and sales of point-of-care testing (POCT) diagnostic reagents. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-09-08. The firm's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
8 Sept 2021
Employees
730

Leadership

Pay as last reported

  • Mr. Chunsheng YeDeputy General Manager
  • Mr. Liang WangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Hangzhou Biotest Biotech employs 730 full-time employees in Health Care sector.
  • POCT diagnostic reagents include reproductive health testing series like hCG reagent.
  • The company's IPO on 8 September 2021 established market presence.

Weaknesses

  • Hangzhou Biotest Biotech has no listed competitors in the Health Care sector.
  • The company lacks product diversity beyond diagnostic reagents.
  • No mention of international expansion plans in the facts provided.

Opportunities

  • Reproductive health testing series like hCG reagent has growing market demand.
  • Infectious disease testing series such as adenovirus reagent meets public health needs.
  • Tumor marker testing series including alpha fetoprotein reagent offers growth potential.

Threats

  • Drug abuse testing series like morphine reagent faces regulatory challenges.
  • Myocardial marker detection series such as dimer reagent may encounter market saturation.
  • No data on global market trends affecting Hangzhou Biotest Biotech.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.